Amneal Pharmaceuticals, Inc. (AMRX)
NASDAQ: AMRX · Real-Time Price · USD
7.83
-0.04 (-0.51%)
Feb 21, 2025, 4:00 PM EST - Market closed
Amneal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Amneal Pharmaceuticals stock have an average target of 10, with a low estimate of 8.00 and a high estimate of 12. The average target predicts an increase of 27.71% from the current stock price of 7.83.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 11, 2024.
Analyst Ratings
The average analyst rating for Amneal Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 2 | 2 | 2 | 2 |
Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 6 | 6 | 5 | 5 | 5 | 5 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Piper Sandler | Piper Sandler | Buy Maintains $9 → $11 | Buy | Maintains | $9 → $11 | +40.49% | Nov 11, 2024 |
Truist Securities | Truist Securities | Strong Buy Maintains $10 → $12 | Strong Buy | Maintains | $10 → $12 | +53.26% | Oct 2, 2024 |
JP Morgan | JP Morgan | Sell → Hold Upgrades $9 | Sell → Hold | Upgrades | $9 | +14.94% | Sep 6, 2024 |
Barclays | Barclays | Buy Maintains $8 → $10 | Buy | Maintains | $8 → $10 | +27.71% | Aug 13, 2024 |
Truist Securities | Truist Securities | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +27.71% | Aug 12, 2024 |
Financial Forecast
Revenue This Year
2.83B
from 2.39B
Increased by 18.06%
Revenue Next Year
2.93B
from 2.83B
Increased by 3.82%
EPS This Year
0.62
from -0.48
EPS Next Year
0.72
from 0.62
Increased by 14.98%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 |
---|---|---|---|
High | 2.9B | 3.1B | 3.3B |
Avg | 2.8B | 2.9B | 3.0B |
Low | 2.7B | 2.8B | 2.7B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | 21.7% | 10.0% | 13.1% |
Avg | 18.1% | 3.8% | 3.6% |
Low | 13.3% | -1.9% | -7.3% |
EPS Forecast
EPS | 2024 | 2025 | 2026 |
---|---|---|---|
High | 0.66 | 0.85 | 0.86 |
Avg | 0.62 | 0.72 | 0.81 |
Low | 0.59 | 0.57 | 0.75 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 |
---|---|---|---|
High | - | 35.6% | 19.9% |
Avg | - | 15.0% | 12.2% |
Low | - | -9.0% | 5.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.